Vanguard Global Advisers’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$222K Buy
81,583
+9,966
+14% +$33.2K ﹤0.01% 2446
2026
Q2
$269K Hold
71,617
– – ﹤0.01% 2378
2026
Q1
$337K Buy
+71,617
New +$364K ﹤0.01% 2206

Other funds holding CTMX

Vanguard Global Advisers's CTMX Position: Q3 2026 in Review

Vanguard Global Advisers increased its CytomX Therapeutics (CTMX) stake by 14% in Q3 2026, buying an estimated $33.2K and bringing the position to 81,583 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

Vanguard Global Advisers first reported a position in CTMX in Q1 2026 and has held it in 3 quarters since. The position peaked at $337K in Q1 2026. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Vanguard Global Advisers held 81,583 shares of CytomX Therapeutics worth $222K as of Q3 2026.
  • Vanguard Global Advisers bought 9,966 CytomX Therapeutics shares in Q3 2026, an estimated $33.2K.
  • CytomX Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2446 holding.
  • Vanguard Global Advisers first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's CytomX Therapeutics position peaked at $337K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.